Key Takeaways UHS posted Q4 EPS of $5.88, missing estimates as admissions and patient days fell short.Universal Health saw 9% higher operating costs, driven by wages, supplies and expenses.UHS guided 2026 revenue of $18.417-$18.789B and EPS of $22.64-$24.52.Universal Health Services, Inc. (UHS) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $5.88, which missed the Zacks Consensus Estimate by 0.6%. The bottom line soared 19.5% year over year.Net revenues of $4.49 billion improved 9.1% year ...

On February 17, 2026, Abdiel Capital Advisors disclosed in an SEC filing that it sold 1,075,738 shares of Appian (NASDAQ:APPN), an estimated $38.32 million trade based on quarterly average pricing. What happened According to an SEC filing dated February 17, 2026, Abdiel Capital Advisors sold 1,075,738 shares of Appian during the fourth quarter of 2025. The estimated transaction value was $38.32 million, calculated using the average closing price for the quarter. Meanwhile, the quarter-end value of the Ap ...

Key Takeaways Teladoc Health reported a Q4 adjusted loss of 14 cents, narrower than estimates and year-ago loss.TDOC saw 19% international growth and 5% Integrated Care revenue growth, boosting results.BetterHelp revenues fell 6% in Q4, with 2026 guidance projecting further declines in the segment.Teladoc Health, Inc. (TDOC) reported a fourth-quarter 2025 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents. The company posted a loss of 28 cents in the year-a ...

Core Viewpoint - Universal Health Services, Inc. (UHS) is expected to report its fourth-quarter 2025 results on February 25, 2026, with earnings estimated at $5.91 per share and revenues of $4.48 billion [1]. Earnings Estimates - The fourth-quarter earnings estimate has seen two upward revisions in the last 60 days, indicating a year-over-year increase of 20.1% [2]. - The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 9% [2]. Full-Year Projections - For the full year 2025, the revenue estimate for UHS is $17.36 billion, reflecting a 9.7% year-over-year increase [5]. - The consensus estimate for full-year EPS is $21.80, indicating a growth of 31.3% year-over-year [5]. Recent Performance - UHS has consistently beaten consensus earnings estimates in the last four quarters, with an average surprise of 15.2% [5]. Earnings Prediction Model - The current Earnings ESP for UHS is 0.00%, and it holds a Zacks Rank of 2 (Buy), which does not strongly indicate an earnings beat this time [6]. Factors Influencing Q4 Results - UHS is projected to achieve 20.1% EPS growth and 9% revenue growth for Q4 2025, driven by strong performance in Acute Care and Behavioral segments [9]. - The Acute Care Hospital Services segment is expected to generate net revenues of $2.51 billion, representing an 8.3% year-over-year growth [10]. - The Behavioral Health Care Services segment is estimated to have net revenues of $1.97 billion, indicating a 10% increase from the prior year [11]. Operating Income Expectations - The operating income for Acute Care Hospital Services is projected to grow by 11.2% year-over-year, while the Behavioral Health Care Services segment is expected to see a 20.9% increase [11]. Cost Pressures - Rising total operating expenses are anticipated to increase by nearly 8%, primarily due to higher salaries, wages, and supply costs, which may impact margins and create uncertainty around earnings beats [12]. - Salaries, wages, and benefits are expected to rise by 8.4% year-over-year, while supply expenses are projected to increase by 6.7% [12]. Industry Performance Comparison - Other companies in the medical sector, such as HCA Healthcare, Ensign Group, and Encompass Health, have reported their fourth-quarter results, with varying degrees of success influenced by similar cost pressures [13][14][15].

Core Insights - Pediatrix Medical Group, Inc. reported fourth-quarter 2025 adjusted EPS of 50 cents, missing the Zacks Consensus Estimate by 4.9%, with a year-over-year decline of 2% [1] - Net revenues for the quarter decreased by 1.7% year over year to $493.8 million, slightly exceeding the Zacks Consensus Estimate by 0.5% [1] Financial Performance - Full-year 2025 net revenues totaled $1.9 billion, a decline of 4.9% year over year, aligning with the Zacks Consensus Estimate [5] - Adjusted EPS for the full year was $2.04, reflecting a 35.1% increase year over year, but missing the Zacks Consensus Estimate of $2.07 [5] - Full-year adjusted EBITDA was $275.6 million, up 23% year over year, while total operating expenses decreased by 18.1% to $1.7 billion [6] Revenue and Expense Analysis - Same-unit revenues increased by 4% year over year in Q4 2025, falling short of the growth estimate and Zacks Consensus Estimate of 6.8% [7] - Same-unit revenues from net reimbursement-related factors grew by 6.7% year over year, driven by improved patient acuity and favorable collection activity, exceeding both the Zacks Consensus Estimate and internal model estimates [8] - Total operating expenses for Q4 were $445 million, down 3.9% year over year, but higher than the estimated $415.4 million [10] Cash Flow and Share Repurchase - As of December 31, 2025, Pediatrix Medical had cash and cash equivalents of $375.2 million, up from $229.9 million a year prior, with no outstanding borrowings on its revolving credit facility [12] - The company repurchased 4.1 million shares for $83.8 million during 2025, with $166.2 million remaining available in the buyback program [14] 2026 Outlook - Management projects adjusted EBITDA for 2026 to be between $280 million and $300 million, with net income estimated between $155.1 million and $169.7 million [15] - Interest expenses are forecasted at $34 million, with income tax expenses expected to range from $57.4 million to $62.8 million [15]

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: For-profit hospital operator Community Health Systems is looking to slow down its aggressive pace of divestitures as it focuses on growth in its core markets, executives said on an earnings call Thursday. The Tennessee-based system has divested about 35% of its hospital portfolio since 2019 in an attempt to  deleverage its portfolio and free up ...

Key Takeaways CYH posted break-even Q4 EPS, topping estimates and improving from prior-year loss.Community Health Systems saw Q4 revenue fall 4.9% as admissions and patient days declined.CYH forecasts 2026 revenue of $11.6B-$12B and EBITDA of $1.34B-$1.49B, below 2025 levels.Community Health Systems, Inc. (CYH) reported break-even earnings per share in the quarter, outperforming the Zacks Consensus Estimate of a loss of 32 cents. The bottom line improved from a loss of 42 cents in the prior-year quarter.Net ...

Core Viewpoint - HCA Healthcare, Inc. is a leading U.S. healthcare provider with a market capitalization of $120.82 billion, focusing on high-quality patient care and innovative treatments [1] Stock Performance - HCA's stock has increased by 67.8% over the past 52 weeks and is up 15.7% year-to-date (YTD), although it is down 2.3% from its 52-week high of $552.90 reached on February 12 [2] - The stock has outperformed the broader S&P 500 Index, which gained 11.8% over the past 52 weeks but is down marginally YTD, and the State Street Health Care Select Sector SPDR ETF (XLV), which increased by 7.7% over the same period [3] Financial Results - HCA reported a 6.7% year-over-year (YOY) revenue increase to $19.51 billion for the fourth quarter, with an adjusted EPS of $8.01, up 28.8% YOY, exceeding Wall Street expectations [4] - For the current quarter, analysts expect HCA's EPS to rise by 11.2% YOY to $7.17, with projections of $30.20 for fiscal 2026 (up 7.1%) and $33.35 for fiscal 2027 (up 10.4%) [5] Analyst Ratings - Among 25 Wall Street analysts, the consensus rating for HCA's stock is a "Moderate Buy," consisting of 14 "Strong Buy" ratings, one "Moderate Buy," nine "Holds," and one "Strong Sell," indicating a slight decrease in bullish sentiment compared to three months ago [6]

Core Viewpoint - HCA Healthcare has shown strong stock performance and financial results, indicating potential for long-term investment despite regulatory uncertainties [1][2][6]. Financial Performance - In the fourth quarter of 2025, HCA Healthcare reported a revenue increase of 6.7% to $19.5 billion, driven by growth in hospital admissions [3]. - Adjusted earnings per share rose by 28.8% to $8.01 during the same period [3]. Revenue Guidance - For fiscal 2026, HCA Healthcare expects revenue between $76.5 billion and $80 billion, suggesting a year-over-year growth of approximately 3.5% [4]. - The company faces regulatory challenges, particularly with the expiration of enhanced premium tax credits, which could impact demand and revenue [5]. Growth Opportunities - HCA Healthcare is positioned to benefit from increasing demand for medical care due to an aging population [6]. - The company is investing in initiatives, including artificial intelligence, to improve patient outcomes and grow market share [6]. Market Position - HCA Healthcare has established strong relationships with physicians, patients, and third-party payers, which may help it navigate regulatory volatility [7]. - Despite potential challenges, the company's position in the healthcare industry and growth opportunities suggest it could deliver above-average returns in the long run [7].

Core Insights - Tenet Healthcare Corporation (THC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.70, exceeding the Zacks Consensus Estimate by 15.2%, with a year-over-year increase of 36.6% [1] - Net operating revenues rose 8.9% year over year to $5.53 billion, surpassing the consensus mark by 1.4% [1] Financial Performance - Adjusted net income for the quarter was $413 million, a 25.2% increase year over year [3] - Adjusted EBITDA improved 12.9% year over year to $1.18 billion, exceeding the estimate of $1.13 billion, with an adjusted EBITDA margin expanding 70 basis points to 21.4% [3] - Salaries, wages, and benefits costs increased 6.1% year over year to $2.2 billion, while supply costs rose 8.6% and net other operating expenses increased 10.8% [4] Segment Performance - Hospital Operations and Services segment recorded net operating revenues of $4.09 billion, up 7.3% year over year, driven by improved Medicaid supplemental revenues and a favorable payer mix [5] - Adjusted EBITDA for the Hospital segment climbed 16.4% year over year to $603 million, with an adjusted EBITDA margin of 14.7%, improving 110 basis points [6] - Ambulatory Care segment's net operating revenues rose 13.8% year over year to $1.43 billion, supported by facility buyouts and expansion of service lines, with adjusted EBITDA at $580 million, a 9.4% increase [7] Financial Position - As of December 31, 2025, Tenet Healthcare had cash and cash equivalents of $2.88 billion, down from $3.02 billion at the end of 2024, while total assets increased to $29.7 billion from $28.9 billion [8] - Long-term debt amounted to $13.1 billion, slightly up from the previous year, with total shareholders' equity increasing to $4.22 billion from $4.17 billion [9] Cash Flow and Share Repurchase - Tenet generated $3.5 billion of net cash from operations in 2025, a 72.9% year-over-year increase, with free cash flows improving 126.7% to $2.5 billion [11] - The company repurchased $198 million in shares during the fourth quarter and $1.4 billion in 2025, with a remaining share repurchase authorization of approximately $1.49 billion [12] 2026 Outlook - Net operating revenues for 2026 are projected to be between $21.5 billion and $22.3 billion, higher than the $21.3 billion in 2025 [13] - Adjusted EBITDA is expected to range from $4.485 billion to $4.785 billion, with an estimated adjusted EBITDA margin of 20.9-21.5%, indicating a potential decline from 2025 [14] - Free cash flow is anticipated to remain between $2.94 billion and $3.29 billion, with capital expenditures projected at $700-$800 million [15]